Patients who underwent endoscopic endonasal surgery for hypothalamic-pituitary disorders and skull base diseases
Conditions
Interventions
None listed
Sponsors
Saitama Medical Center, Saitama Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Individuals who meet all of the following criteria: Underwent EES for a skull base lesion during the study period (October 1, 2022, to September 30, 2024; two years). Adults (18 years or older). Have follow-up data for at least 30 days from the date of surgery.
Exclusion criteria
Exclusion criteria: Individuals who meet any of the following criteria will be excluded: Underwent surgery primarily for the closure of a CSF leak. Underwent transnasal surgery for the treatment of an infection (e.g., abscess, fungal infection). Minors (under 18 years old). Underwent combined transnasal and craniotomy procedures. Severe liver dysfunction (Child-Pugh classification B or C). Patients with preoperative conditions or medication history that may result in immunosuppression, including: HIV infection Use of immunosuppressive drugs: Corticosteroids (e.g., prednisolone)* Calcineurin inhibitors (e.g., cyclosporine, tacrolimus) Antimetabolites (e.g., mycophenolate mofetil, mizoribine, azathioprine) mTOR inhibitors (e.g., everolimus) Infliximab or similar agents Pregnant individuals *The use of corticosteroids for replacement therapy in cases of anterior pituitary insufficiency or for perioperative management concerns will not be considered an exclusion criterion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The presence or absence of SSI within 30 days from the date of surgery will be evaluated as an outcome measure. However, information on infections that occur beyond 31 days and resemble SSI will also be collected and presented as a reference item. | — |
Countries
Japan
Contacts
Public ContactYuki Kawaguchi
Saitama Medical Center, Saitama Medical University Department of Neurosurgery
Outcome results
None listed